Lack of vasopressin does not prevent the behavioural and endocrine changes induced by chronic unpredictable stress

Brain Research Bulletin

Volumn 84, Issue 1, 2011, Pages 45-52

  Varga, Janos ^a   Domokos, Agnes ^a   Barna, Istvan ^a   Jankord, Ryan ^b   Bagdy, Gyorgy ^c   Zelena, Dora ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b AIR FORCE RESEARCH LABORATORY   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

ACTH; Corticosterone; Elevated plus maze; Forced swim; POMC

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; MESSENGER RNA; NEUROPEPTIDE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT; CHRONIC UNPREDICTABLE STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; ENDOCRINE SYSTEM; FOOD INTAKE; FORCED SWIMMING TEST; HYPOPHYSIS; HYPOPHYSIS ADRENAL SYSTEM; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS; THYMUS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BODY WEIGHT; CORTICOSTERONE; DEPRESSION; DRINKING; EATING; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE; PITUITARY-ADRENAL SYSTEM; RATS; RATS, BRATTLEBORO; STRESS, PSYCHOLOGICAL; VASOPRESSINS;

EID: 78650304525     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.09.014     Document Type: Article

References (55)

1. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front. Neuroendocrinol. 1994, 15:321-350.
2. Aguilera G., Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Pept. 2000, 96:23-29.
3. Bergstrom A., Jayatissa M.N., Thykjaer T., Wiborg O. Molecular pathways associated with stress resilience and drug resistance in the chronic mild stress rat model of depression: a gene expression study. J. Mol. Neurosci. 2007, 33:201-215.
4. Bielsky I.F., Hu S.B., Szegda K.L., Westphal H., Young L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 2004, 29:483-493.
5. Bohus B., de Wied D. The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Prog. Brain Res. 1998, 119:555-573.
6. Burlet A., Tonon M.C., Tankosic P., Coy D., Vaudry H. Comparative immunocytochemical localization of corticotropin releasing factor (CRF-41) and neurohypophysial peptides in the brain of Brattleboro and Long-Evans rats. Neuroendocrinology 1983, 37:64-72.
7. Dallman M.F. Stress update adaptation of the hypothalamic-pituitary-adrenal axis to chronic stress. Trends Endocrinol. Metab. 1993, 4:62-69.
8. Dallman M.F., la Fleur S.E., Pecoraro N.C., Gomez F., Houshyar H., Akana S.F. Minireview: glucocorticoids - food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 2004, 145:2633-2638.
9. Domokos A., Mergl Z., Barna I., Makara G.B., Zelena D. Congenital vasopressin deficiency and acute and chronic opiate effects on hypothalamo-pituitary-adrenal axis activity in Brattleboro rats. J. Endocrinol. 2008, 196:113-121.
10. Duncko R., Brtko J., Kvetnansky R., Jezova D. Altered function of peripheral organ systems in rats exposed to chronic mild stress model of depression. Cell. Mol. Neurobiol. 2001, 21:403-411.
11. Engelmann M., Landgraf R., Wotjak C.T. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front. Neuroendocrinol. 2004, 25:132-149.
12. Gold P.W., Goodwin F.K., Reus V.I. Vasopressin in affective illness. Lancet 1978, 1:1233-1236.
13. Gold P.W., Weingartner H., Ballenger J.C., Goodwin F.K., Post R.M. Effects of 1-desamo-8-d-arginine vasopressin on behaviour and cognition in primary affective disorder. Lancet 1979, 2:992-994.
14. Gregus A., Wintink A.J., Davis A.C., Kalynchuk L.E. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav. Brain Res. 2005, 156:105-114.
15. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.P., Soubrie P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6370-6375.
16. Hlavacova N., Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm. Behav. 2008, 54:90-97.
17. Holsboer F., Ising M. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur. J. Pharmacol. 2008, 583:350-357.
18. Holsboer F., Ising M. Stress hormone regulation: biological role and translation into therapy. Annu. Rev. Psychol. 2010, 61:81-109. (C1-C11).
19. Homberg J.R., van den Akker M., Raaso H.S., Wardeh G., Binnekade R., Schoffelmeer A.N., de Vries T.J. Enhanced motivation to self-administer cocaine is predicted by self-grooming behaviour and relates to dopamine release in the rat medial prefrontal cortex and amygdala. Eur. J. Neurosci. 2002, 15:1542-1550.
20. Jeljeli M., Strazielle C., Caston J., Lalonde R. Effects of ventrolateral-ventromedial thalamic lesions on motor coordination and spatial orientation in rats. Neurosci. Res. 2003, 47:309-316.
21. Korte S.M. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci. Biobehav. Rev. 2001, 25:117-142.
22. Landgraf R., Gerstberger R., Montkowski A., Probst J.C., Wotjak C.T., Holsboer F., Engelmann M. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J. Neurosci. 1995, 15:4250-4258.
23. Lapiz-Bluhm M.D., Bondi C.O., Doyen J., Rodriguez G.A., Bedard-Arana T., Morilak D.A. Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats. J. Neuroendocrinol. 2008, 20:1115-1137.
24. Lee B., Yang C., Chen T.H., al-Azawi N., Hsu W.H. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am. J. Physiol. 1995, 269:E1095-E1100.
25. McEwen B.S. Mood disorders and allostatic load. Biol. Psychiatry 2003, 54:200-207.
26. Meynen G., Unmehopa U.A., van Heerikhuize J.J., Hofman M.A., Swaab D.F., Hoogendijk W.J. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: a preliminary report. Biol. Psychiatry 2006, 60:892-895.
27. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
28. Mlynarik M., Zelena D., Bagdy G., Makara G.B., Jezova D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm. Behav. 2007, 51:395-405.
29. Murphy H.M., Wideman C.H. Vasopressin deficiency and the modulation of consummatory behavior. Peptides 1991, 12:319-322.
30. Popova N.K., Naumenko K.S., Maslova L.N., Amstislavskaya T.G., Melidi N.N., Bulygina V.V., Ivanova L.N. Hypothalamic tryptophan hydroxylase and the hypothalamic-pituitary-adrenocortical response to water deprivation and hydration in vasopressin-deficient and normal rats. Pflugers Arch. 2002, 444:372-377.
31. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 1978, 47:379-391.
32. Purba J.S., Hoogendijk W.J., Hofman M.A., Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 1996, 53:137-143.
33. Raadsheer F.C., Tilders F.J., Swaab D.F. Similar age related increase of vasopressin colocalization in paraventricular corticotropin-releasing hormone neurons in controls and Alzheimer patients. J. Neuroendocrinol. 1994, 6:131-133.
34. Schlosser S.F., Almeida O.F., Patchev V.K., Yassouridis A., Elands J. Oxytocin-stimulated release of adrenocorticotropin from the rat pituitary is mediated by arginine vasopressin receptors of the V1b type. Endocrinology 1994, 135:2058-2063.
35. Schmale H., Ivell R., Breindl M., Darmer D., Richter D. The mutant vasopressin gene from diabetes insipidus (Brattleboro) rats is transcribed but the message is not efficiently translated. EMBO J. 1984, 3:3289-3293.
36. Schulkin J., Gold P.W., McEwen B.S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 1998, 23:219-243.
37. Scott L.V., Dinan T.G. Vasopressin as a target for antidepressant development: an assessment of the available evidence. J. Affect. Disord. 2002, 72:113-124.
38. Selye H., Horava A. Stress research. Science 1953, 117:509.
39. Serradeil-Le Gal C., Wagnon J., Valette G., Garcia G., Pascal M., Maffrand J.P., Le Fur G. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog. Brain Res. 2002, 139:197-210.
40. Tannahill L.A., Dow R.C., Fairhall K.M., Robinson I.C., Fink G. Comparison of adrenocorticotropin control in Brattleboro, Long-Evans, and Wistar rats. Measurement of corticotropin-releasing factor, arginine vasopressin, and oxytocin in hypophysial portal blood. Neuroendocrinology 1988, 48:650-657.
41. Valtin H., Schroeder H.A. Familial hypothalamic diabetes insipidus in rats (Brattleboro strain). Am. J. Physiol. 1964, 206:425-430.
42. van Erp A.M., Kruk M.R., Meelis W., Willekens-Bramer D.C. Effect of environmental stressors on time course, variability and form of self-grooming in the rat: handling, social contact, defeat, novelty, restraint and fur moistening. Behav. Brain Res. 1994, 65:47-55.
43. van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17:284-292.
44. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
45. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997, 134:319-329.
46. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.
47. Wolkowitz O.M., Epel E.S., Reus V.I. Stress hormone-related psychopathology: pathophysiological and treatment implications. World J. Biol. Psychiatry 2001, 2:115-143.
48. Zelena D., Domokos A., Mergl Z., Barna I., Földes A., Kovács K.J., Makara G.B. The role of vasopressin in chronic stress-induced hypothalamo-pituitary-adrenal axis hyperactivity: studies on Brattleboro rats with repeated restraint Dóra. Neuropeptide Research Trends 2007, Nova Publishers, pp. 189-212.
49. Zelena D., Filaretova L., Mergl Z., Barna I., Toth Z.E., Makara G.B. Hypothalamic paraventricular nucleus, but not vasopressin, participates in chronic hyperactivity of the HPA axis in diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E243-E250.
50. Zelena D., Foldes A., Mergl Z., Barna I., Kovacs K.J., Makara G.B. Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin deficient Brattleboro rats. Brain Res. Bull. 2004, 63:521-530.
51. Zelena D., Kiem D.T., Barna I., Makara G.B. Alpha 2-adrenoreceptor subtypes regulate ACTH and beta-endorphin secretions during stress in the rat. Psychoneuroendocrinology 1999, 24:333-343.
52. Zelena D., Langnaese K., Domokos A., Pinter O., Landgraf R., Makara G.B., Engelmann M. Vasopressin administration into the paraventricular nucleus normalizes plasma oxytocin and corticosterone levels in Brattleboro rats. Endocrinology 2009, 150:2791-2798.
53. Zelena D., Mergl Z., Foldes A., Kovacs K.J., Toth Z., Makara G.B. Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E1110-E1117.
54. Zelena D., Mergl Z., Makara G.B. Maternal genotype influences stress reactivity of vasopressin-deficient Brattleboro rats. J. Neuroendocrinol. 2003, 15:1105-1110.
55. Zelena D., Mergl Z., Makara G.B. The role of vasopressin in diabetes mellitus-induced hypothalamo-pituitary-adrenal axis activation: studies in Brattleboro rats. Brain Res. Bull. 2006, 69:48-56.